PNT2258-02: A Pilot Phase II Study of PNT2258 for Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma

Trial Profile

PNT2258-02: A Pilot Phase II Study of PNT2258 for Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma

Completed
Phase of Trial: Phase II

Latest Information Update: 13 Jan 2017

At a glance

  • Drugs Rosomidnar (Primary)
  • Indications Chronic lymphocytic leukaemia; Follicular lymphoma; Mantle-cell lymphoma; Non-Hodgkin's lymphoma
  • Focus Biomarker; Therapeutic Use
  • Sponsors ProNAi Therapeutics
  • Most Recent Events

    • 19 Oct 2016 Status changed from active, no longer recruiting to completed.
    • 06 Jun 2016 Results published in a ProNAi Therapeutics media release.
    • 11 Apr 2016 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top